Your browser doesn't support javascript.
loading
Radiosurgery for brain metastases from ovarian cancer: an analysis of 25 years' experience with Gamma Knife treatment.
Ordoñez, Rosa Maria Leon-Salas; Amendola, Beatriz E; Martinez, Paul F; Wolf, Aizik; Coy, Sammie R; Amendola, Marco.
Afiliação
  • Ordoñez RML; Innovative Cancer Institute, 5995 SW 71 Street, South Miami, FL 33143, United States.
  • Amendola BE; Innovative Cancer Institute, 5995 SW 71 Street, South Miami, FL 33143, United States.
  • Martinez PF; Innovative Cancer Institute, 5995 SW 71 Street, South Miami, FL 33143, United States.
  • Wolf A; Miami Neuroscience Center, 6129 SW 70 Street, South Miami, FL 33143, United States.
  • Coy SR; Miami Neuroscience Center, 6129 SW 70 Street, South Miami, FL 33143, United States.
  • Amendola M; Innovative Cancer Institute, 5995 SW 71 Street, South Miami, FL 33143, United States.
Rep Pract Oncol Radiother ; 24(6): 667-671, 2019.
Article em En | MEDLINE | ID: mdl-31719805
PURPOSE: We present our results in the treatment of brain metastases (BM) from ovarian cancer using Gamma Knife Radiosurgery (GKRS) over the last 25 years in a single institution. BACKGROUND: Gamma Knife Radiosurgery has become increasingly important in the management of brain metastases from ovarian cancer due to improving results from systemic disease and the need for better outcomes. MATERIAL AND METHODS: The medical records of 9 patients with brain metastases from ovarian cancer treated with GKRS between 1993 and 2018 were reviewed. Median age at first treatment was 57 years (range 39-76). Forty-two brain metastases were treated with 16 procedures. Median tumor volume was 1.8cc ranging from 0.2 to 30.3cc (there were five patients with a tumor volume exceeding 10cc). Median prescription dose was 16 Gy. RESULTS: Using Kaplan Meier estimates, the median OS after diagnosis was 48.1 months and the median OS after GKRS was 10.6 months (ranging from 2.5 to 81 months). The Kaplan Meier survival rates were 31.3%, and 6.5% at 2 and 5 years after GKRS, respectively. Treatment procedure was well tolerated and no patient presented with acute or chronic toxicity. Two of 9 patients had a tumor requiring retreatment (local control of 95% 40/42). Two out of the 7 patients evaluated for cause of death expired due to progression of brain metastases and the remaining ones died of systemic disease with brain control. CONCLUSIONS: GKRS for BM from ovarian cancer is a safe and effective modality. Our findings are in agreement with the recent literature indicating that women with brain metastases from ovarian cancer will benefit with radiosurgery and may achieve long term survival with brain control.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Rep Pract Oncol Radiother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Polônia

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Rep Pract Oncol Radiother Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Polônia